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reamble
ver the last decade, there has been an increasing awareness that
e quality of medical care in the United States, which should be
fective, timely, safe, equitable, efficient, and patient-centered
edical care, has the potential for improvement (1).
Consistent with this focus on healthcare quality, the Amer-
an College of Cardiology Foundation (ACCF) and the
merican Heart Association (AHA) work together as a
ading force to define “what works in medicine,” by devel-
ing ACCF/AHA practice guidelines statements and creat-
g performance measures in order to define what should (or
ould not be done) to ensure that patients with cardiovascu-
r disease receive optimal care (Table 1).
The ACCF/AHA Task Force on Performance Measures is
arged with identifying the clinical topics appropriate for the
velopment of performance measures and with assembling
riting committees composed of clinical and methodological
perts. When appropriate, these committees have included
presentation from other organizations involved in the care of
tients with the condition of focus. Committee members are
formed about the methodology of performance measure de-
lopment (2) and are instructed to construct measures for broad
e that meet these criteria. Writing committees are also in-
ructed to strive to create measures that minimize the reporting
rden for participants and measures that are aligned with
tional standards so as to promote harmony among measures.
All selected measures pose potential challenges to im-
ementation that could result in unintended consequences.
he manner in which these issues are addressed is depen-
nt on several factors, including the measure design,
mli
ti
th
po
A
te
to
th
no
m
fo
in
op
re
m
is
a
do
th
ar
m
ou
qu
pa
ex
ifi
ca
co
1
T
ci
P
F
ch
co
pa
m
H
ad
ou
ce
pe
in
at
da
pa
nu
re
pr
su
of
(a
m
se
on
on
3
Ta
To
He
Ch
di
Hy
ST
m
Ca
At
Pr
ca
Pe
Pe
Ca
Fo
Im
So
1814 Bonow et al. JACC Vol. 59, No. 20, 2012
ACCF/AHA/AMA-PCPI Heart Failure Performance Measures May 15, 2012:1812–32ethod of data collection, performance attribution, base-
ne performance rates, reporting methods used, and incen-
ves linked to these reports. The ACCF/AHA encourages
ose interested in implementing these measures for pur-
ses beyond quality improvement to work with the
CCF/AHA to consider these complex issues in pilot
sting projects, assess limitations and confounding fac-
rs, and guide refinements of the measures to enhance
eir utility for these additional purposes.
The current heart failure (HF) performance measure set is
table for several reasons. First, an earlier group of perfor-
ance measures was retired when the measures were not
und to reflect quality of care delivered when implemented
the community setting, given that there was limited
portunity for further improvement, and/or they were al-
ady captured by other performance measure sets. Retire-
ent of measures that no longer serve their intended purpose
an important part of the performance measure life cycle. As
result of its activities, the committee has reduced the
cumentation burden on clinicians and hospitals in the hope
at this will thereby allow them to focus on more critical
eas of quality measurement and improvement. The com-
ittee has also extended some inpatient measures to the
tpatient setting to emphasize the need to measure the
ality of care over time, often across providers who care for
tients with HF. Finally, the performance measures were
tended to assess functional outcomes. This new and mod-
ed HF measure set thus spans the spectrum of quality of
re and, once implemented, should lead to improved out-
mes in patients with HF.
Eric D. Peterson, MD, MPH, FACC, FAHA
ble 1. ACCF/AHA Performance Measure Sets
pic
Original
Publication Date P
art failure (3) 2005 ACC
ACC/
ronic stable coronary artery
sease (5)
2005
pertension (7) 2005
-elevation and non–ST-elevation
yocardial infarction (8)
2006
rdiac rehabilitation (10) 2007
rial fibrillation (12) 2008
imary prevention of
rdiovascular disease (13)
2009
ripheral artery disease (14) 2010 ACCF/AH
rcutaneous coronary intervention 2012* ACCF
rdiac imaging 2012* ACCF
AACVPR indicates American Association of Cardiovascular and Pulmonary Reha
undation; ACR, American College of Radiology; AHA, American Heart Associati
provement; NCQA, National Committee for Quality Assurance; SCAI, Society for
ciety for Vascular Medicine; SVN, Society for Vascular Nursing; and SVS, Soc
*Planned publication date.Chair, ACCF/AHA Task Force on Performance Measures w. Introduction
he ACCF/AHA/American Medical Association–Physi-
an Consortium for Performance Improvement (AMA-
CPI) 2011 Performance Measures for Adults With Heart
ailure Writing Committee (the writing committee) was
arged with the development of performance measures
ncerning the diagnosis, treatment, and outcomes of
tients with HF. The purpose of this effort is to provide
easures that can be used to improve care for patients with
F. This updated performance measure document set
dresses both in-hospital care and continuing care in the
tpatient setting. Many guideline-recommended pro-
sses were considered but ultimately not translated into
rformance measures. Decisions about which measures to
clude were based on many factors. Common consider-
ions included the complexity of the guideline recommen-
tions (making translation difficult), ability to define
tients to be included in the denominator without a large
mber of exclusions, and feasibility of collecting the
quired data. This document is intended to supersede the
ior publication of HF performance measures (3).
This updated performance measure set presents 9 mea-
res, including 3 new measures and 6 revised measures,
which 3 measures are designated as quality metrics
ppropriate for internal quality improvement only). Two
easures apply to care in both the inpatient and outpatient
tting, 5 measures address care in the outpatient setting
ly, and 2 measures address care in the inpatient setting
ly. In addition, 8 earlier measures have been retired. The
quality metrics represent test measures that address areas
g Organizations Status
npatient measures Updated 2011 (4)
A-PCPI—outpatient
easures
A/AMA-PCPI Updated 2011 (6)
A/AMA-PCPI Updated 2011 (6)
CC/AHA Updated 2008 (9)
PR/ACC/AHA Updated 2010 (referral measures only) (11)
A/AMA-PCPI
A/ACCF
CAI/SIR/SVM/SVN/SVS
AI/AMA-PCPI/NCQA
R/AMA-PCPI/NCQA
; ACC, American College of Cardiology; ACCF, American College of Cardiology
-PCPI, American Medical Association–Physician Consortium for Performance
Angiography and Interventions; SIR, Society of Interventional Radiology; SVM,
Vascular Surgery.artnerin
/AHA—i
AHA/AM
m
ACC/AH
ACC/AH
A
AACV
ACC/AH
AH
A/ACR/S
/AHA/SC
/AHA/AC
bilitation
on; AMA
Cardiac
iety fororthy of measurement, but for considerations such as
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ese are not considered appropriate for use for public
countability at this time. A summary of the new measure
ble 2. ACCF/AHA/AMA-PCPI 2011 HF Measurement Set
easure Description*
LVEF assessment Percentage of patients aged 18 y with
for whom the quantitative or qualitative
or prior (any time in the past) LVEF asse
documented within a 12-mo period
LVEF assessment Percentage of patients aged 18 y with
discharge diagnosis of HF with documen
hospital record of the results of an LVEF
performed either before arrival or during
OR documentation in the hospital record
assessment is planned after discharge
Symptom and activity
assessment
Percentage of patient visits for those pa
with a diagnosis of HF with quantitative
evaluation of both current level of activi
symptoms documented
Symptom management† Percentage of patient visits for those pa
with a diagnosis of HF and with quantita
evaluation of both level of activity AND c
documented in which patient symptoms
remained consistent with treatment goa
assessment OR patient symptoms have
clinically important deterioration since la
with a documented plan of care
Patient self-care
education††
Percentage of patients aged 18 y with
who were provided with self-care educa
elements of education during 1 visit w
period
Beta-blocker therapy for
LVSD (outpatient and
inpatient setting)
Percentage of patients aged 18 y with
with a current or prior LVEF of 40% w
prescribed beta-blocker therapy with bis
or sustained-release metoprolol succina
12-mo period when seen in the outpatie
hospital discharge
ACE inhibitor or ARB therapy
for LVSD (outpatient and
inpatient setting)
Percentage of patients aged 18 y with
with a current or prior LVEF of 40% w
prescribed ACE inhibitor or ARB therapy
12-mo period when seen in the outpatie
hospital discharge
Counseling about ICD
implantation for patients
with LVSD receiving
combination medical
therapy††
Percentage of patients aged 18 y with
with current LVEF 35% despite ACE in
beta-blocker therapy for at least 3 mo w
counseled about ICD implantation as a t
for the prophylaxis of sudden death
Postdischarge appointment
for HF patients
Percentage of patients, regardless of a
from an inpatient facility to ambulator
health care with a principal discharge
for whom a follow-up appointment wa
documented, including location, date,
follow-up office visit or home healthca
specified)
ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-
sociation–Physician Consortium for Performance Improvement; ARB, angioten
EF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfun
*Please refer to the complete measures for comprehensive information, inclu
†Test measure designated for use in internal quality improvement programs
r performance, physician ranking, or public reporting programs.
†New measure.t is presented in Table 2. pr.1. Scope of the Problem
F is a major and growing public health problem in the
nited States. For a detailed discussion of the scope of the
Care Setting Level of Measurement
osis of HF
of a recent
is
Outpatient Individual practitioner
ipal
the
ment
lization,
EF
Inpatient ● Individual practitioner
● Facility
ed 18 y
of an
linical
Outpatient Individual practitioner
ed 18 y
ults of an
ymptoms
proved or
last
trated
sment
Outpatient Individual practitioner
nosis of HF
3
12-mo
Outpatient Individual practitioner
nosis of HF
e
carvedilol,
within a
g or at
Inpatient and outpatient ● Individual practitioner
● Facility
nosis of HF
e
ithin a
g or at
Inpatient and outpatient ● Individual practitioner
● Facility
nosis of HF
RB and
e
t option
Outpatient Individual practitioner
charged
r home
is of HF
uled and
e for a
(as
Inpatient Facility
ng enzyme; AHA, American Heart Association; AMA-PCPI, American Medical
ceptor blocker; HF, heart failure; ICD, implantable cardioverter-defibrillator;
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MA-PCPI 2011 HF performance measurement set (4).
.2. Structure and Membership of the
riting Committee
he members of the ACCF/AHA/AMA-PCPI 2011 Perfor-
ance Measures for Adults With Heart Failure Writing
ommittee included clinicians specializing in cardiology,
ternal medicine, family medicine, preventive medicine,
spital medicine, cardiac electrophysiology, and cardiovas-
lar nursing, as well as people with expertise in performance
easure development, implementation, and testing. The writ-
g committee also included patient/consumer representa-
ves, a payer representative, representatives from the ACCF/
HA Heart Failure Guideline Writing Committee, and the
CCF/AHA/AMA-PCPI Coronary Artery Disease/Hyperten-
on Performance Measures Writing Committee to ensure
nsistency across these clinical documents. The writing
mmittee also included representatives of the American
cademy of Family Physicians, the American Academy of
ospice and Palliative Medicine, the American Nurses As-
ciation, the American Society of Health-System Pharma-
sts, the Heart Rhythm Society, and the Society of Hospital
edicine.
.3. Disclosure of Relationships With
dustry and Other Entities
he work of the writing committee was supported exclusively
the ACCF, AHA, and AMA-PCPI without commercial
pport. Writing committee members volunteered their time
this effort. Meetings of the writing committee were
nfidential and attended only by committee members and
aff from the ACCF, AHA, AMA-PCPI, The Joint Commis-
on, and the National Committee for Quality Assurance to
omote harmonization across similar measure sets as de-
ribed further below. Writing committee members were
quired to declare in writing all relationships with industry
d other entities relevant to this topic. Less than 50% of the
riting committee members have relationships with industry
d other entities relevant to this topic, in accordance with
andard requirements of the ACCF and AHA. Please see
ppendix A for relevant relationships of the writing commit-
e and Appendix B for relevant peer reviewer relationships
the peer reviewers.
.4. Review and Endorsement
etween August 18, 2009, and September 20, 2009, the
CCF/AHA/AMA-PCPI 2011 Performance Measures for
dults With Heart Failure” underwent a 30-day public
mment period during which time ACCF, AHA, and AMA-
CPI members, as well as other healthcare professionals and
embers of the general public, had an opportunity to review
d comment on the draft document before its final approval
d publication. An official peer and content review of the full
cument was also conducted with 2 peer reviewers nomi-
ted by the ACCF and 2 reviewers nominated by the AHA.
dditional comments were sought from clinical content
perts and performance measurement experts. foThe “ACCF/AHA/AMA-PCPI 2011 Performance Mea-
res for Adults With Heart Failure” was adopted by the
CCF Board of Trustees and AHA Science Advisory and
oordinating Committee in December 2011 and approved by
e AMA-PCPI in December 2011. These measures will be
viewed for currency once annually and updated as needed.
hey should be considered valid until either updated or
scinded by the ACCF/AHA Task Force on Performance
easures and the AMA-PCPI.
. Methodology
he development of performance measures involves iden-
fication of a set of measures targeted to a particular
tient population, observed over a particular time period.
o achieve this goal, the ACCF/AHA Task Force on
erformance Measures has outlined and published the
ethodology of sequential tasks required for the develop-
ent of process-of-care measures, as well as for outcomes
easures suitable for public reporting (2,15,16). In addi-
on, the AMA-PCPI has developed a work group charge
at outlines the process steps that should be followed by
riting committees that develop performance measures
7). The following sections outline how the writing
mmittee applied these methodologies.
.1. Definition of Heart Failure
he “ACC/AHA 2005 Guideline Update for the Diagnosis
d Management of Chronic Heart Failure in the Adult” (18)
assified HF into 4 stages (Table 3). For purposes of this
cument, only the latter 2 stages, which qualify for the
aditional diagnosis of HF (stages C and D), were considered
ble 3. Stages of HF
age Description
Patients at high risk for HF but without structural heart disease
or symptoms of HF (e.g., patients with hypertension,
atherosclerotic disease, diabetes, obesity, and metabolic
syndrome or patients using cardiotoxins or with a family
history of cardiomyopathy). Such patients have no identified
structural or functional abnormalities of the pericardium,
myocardium, or cardiac valves and have never shown signs or
symptoms of HF
Patients who have developed structural heart disease that is
strongly associated with the development of HF (e.g., previous
myocardial infarction; LV remodeling, including LVH and low
EF; or asymptomatic valvular disease) but without signs or
symptoms of HF
Patients with structural disease who have current or prior
symptoms of HF (e.g., known structural heart disease and
shortness of breath and fatigue, reduced exercise tolerance)
Patients with refractory HF requiring specialized interventions
(e.g., marked symptoms of HF at rest despite maximal medical
therapy—those who are recurrently hospitalized or cannot be
safely discharged from the hospital without specialized
interventions)
EF indicates ejection fraction; HF, heart failure; LV, left ventricular; and LVH,
ft ventricular hypertrophy.
Adapted from Hunt et al (18,19).r inclusion in the measure population. Thus, the inpatient and
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hom established risk factors and structural disorders occur
ithout left ventricular systolic dysfunction or symptoms asso-
ated with HF (stages A and B). In addition, specific diagnosis
des, based on the International Classification of Diseases,
inth Revision, Clinical Modification (ICD-9-CM), which are
ailable on the AMA-PCPI Web site at http://www.ama-
sn.org/apps/listserv/x-check/qmeasure.cgi?submitPCPI,
ould be used to screen and select the target patient
pulation. The inpatient measures are constructed to
clude only those patients with a principal discharge
agnosis of HF, which identifies the condition for which,
retrospect, the patient was admitted to the hospital. The
riting committee also recognizes that in some cases the
incipal discharge diagnosis code may identify patients
r whom these measures may not be appropriate. In part
cause of this, all measures are written with exclusions
at permit clinicians to document the reasons for not
plying particular measures to individual patients. Addi-
onal codes have been added to the ICD-9-CM codes
eviously defined by The Joint Commission and the
enters for Medicare & Medicaid Services (CMS) to
reen and select cohorts for HF performance measures
sed on experience gained during testing/implementation
the 2005 measures.
.2. Identifying Clinically Important Outcomes
o guide the selection of measures to include in the measure
t, the writing committee sought to identify outcomes that
e meaningful to patients with HF and the structures or
ocesses linked with those outcomes. These outcomes in-
ude improving survival rates, decreasing symptoms of HF,
d reducing hospitalizations. A complete list of the desirable
tcomes identified by the writing committee and how they
late to the proposed process measures is included in the
easure specifications (4).
.3. Target Population and Care Period
hese measures are intended for use by physicians, other
igible healthcare professionals, and healthcare systems to
anage the care of patients aged 18 years with HF. They
ay be used to assess performance at the practitioner or
stem level as specified by each measure. The level of
gregation (clinician versus system) will also depend on the
ailability of adequate sample sizes to provide stable esti-
ates of performance.
ble 4. ACCF/AHA/AMA-PCPI 2011 Performance Measures for A
easure Name Diagnostics Patient Edu
LVEF assessment (inpatient setting) ✓
Beta-blocker therapy for LVSD (outpatient
and inpatient setting)
ACE inhibitor or ARB therapy for LVSD
(outpatient and inpatient setting)
Postdischarge appointment for HF patients
ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-
sociation–Physician Consortium for Performance Improvement; ARB, angioten
SD, left ventricular systolic dysfunction..4. Dimensions of Care
iven the multiple domains of providing care that can be
easured, the writing committee identified and explicitly artic-
ated the relevant dimensions of care that should be evaluated.
s part of the methodology, each potential performance measure
as categorized into its relevant dimension of care (Tables 4 and 5).
lassification into dimensions of care facilitated identification of
eas where evidence was lacking and prevented duplication of
easures within the set. Diagnostics, patient education (includ-
g prognosis and etiology), treatment, self-management, and
onitoring of disease status were selected as the relevant
mensions of care for HF performance measures.
In addition, to ensure that the measure set is as comprehen-
ve as possible, the writing committee also compared the
tential measures against the Institute of Medicine domains of
althcare quality (safety, effectiveness, patient-centeredness,
eliness, efficiency, and equity) (1). Although focusing pri-
arily on processes of care, the writing committee also consid-
ed measures of structures of care and outcomes (e.g., symptom
anagement). The measures proposed in this set are intended to
mplement existing National Quality Forum–endorsed HF
tcome measures, such as the CMS 30-day mortality and
admission measures.
.5. Literature Review
s the primary sources for updating the 2005 ACC/AHA HF
rformance measures (3) and deriving new measures as
ecified in the ACC/AHA methodology for developing
ocess measures (2,16) and the AMA “Physician Consor-
um for Performance Improvement (PCPI) Position State-
ent: The Evidence Base Required for Measures Develop-
ent” (20), the writing committee reviewed the “2009
ocused Update Incorporated Into the ACC/AHA 2005
uidelines for the Diagnosis and Management of Heart
ailure in Adults” (19) and the “ACC/AHA 2005 Guideline
pdate for the Diagnosis and Management of Chronic Heart
ailure in the Adult” (18). One co-chair of this writing
mmittee also participated on the writing committees of
th the 2009 HF focused update and the 2005 HF guideline.
addition, the chair of the 2009 HF focused update writing
mmittee was a member of this writing committee. As
rticipants on the guideline writing committees, these indi-
duals were able to offer insights into measurement issues
d provide suggestions for clarity and specificity consistent
ith guideline recommendations. Other sources reviewed
ith HF Set: Dimensions of Care Inpatient Measures Matrix
Treatment Self-Management Monitoring of Disease Status
✓
✓
✓
✓
ng enzyme; AHA, American Heart Association; AMA-PCPI, American Medical
ceptor blocker; HF, heart failure; LVEF, left ventricular ejection fraction; anddults W
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ased Therapy of Cardiac Rhythm Abnormalities” (21), the
FSA 2006 Comprehensive Heart Failure Practice Guide-
ne” (22), the “HFSA 2010 Comprehensive Heart Failure
ractice Guideline” (23), the American College of Physicians
inical practice guideline “Evidence-Based Interventions to
prove the Palliative Care of Pain, Dyspnea, and Depression
the End of Life” (24), and the “ACCF/ASE/ACEP/ASNC/
CAI/SCCT/SCMR 2007 Appropriateness Criteria for Trans-
oracic and Transesophageal Echocardiography” (25).
To avoid duplication of efforts and to harmonize with other
tional measures to the degree possible, the writing com-
ittee also reviewed existing HF measures, including out-
me measures developed by The Joint Commission and
MS, the Agency for Healthcare Research and Quality, the
stitute for Clinical Systems Improvement, CareScience, and
acifiCare and process measures developed by The Joint
ommission, CMS, the IMPROVE HF Registry (26), and the
AND Corporation (27). A comparison of the 2005 and 2011
easure sets is provided in Table 6.
.6. Definition and Selection of Measures
xplicit criteria exist for the development of process perfor-
ance measures so that they accurately reflect the quality of
re. These include evidence of strong scientific validity,
ecification of numerators and denominators, and certainty
at a potential measure is interpretable, applicable, and
asible (2,16). The writing committee sought to identify
easures for which there is strong evidence and clear
nsensus about their importance in the care of HF patients that
e linked to improved outcomes. To determine the processes of
re with adequate evidence support to be considered for
clusion in the performance measurement set, the writing
mmittee reviewed and prioritized the Class I and Class III
commendations from the 2005 HF guideline (18) and the 2009
F focused update (19), with particular attention to changes in
y guideline recommendations on which the 2005 HF perfor-
ance measures (3) were based.
In addition to analyzing the updated guideline recommenda-
ble 5. ACCF/AHA/AMA-PCPI 2011 Performance Measures for A
easure Name Diagnostics Patient Edu
LVEF assessment (outpatient setting) ✓
Symptom and activity assessment
Symptom management*
Patient self-care education* ✓
Beta-blocker therapy for LVSD (outpatient
and inpatient setting)
ACE inhibitor or ARB therapy for LVSD
(outpatient and inpatient setting)
Counseling about ICD implantation for
patients with LVSD receiving combination
medical therapy*
✓
ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-
sociation—Physician Consortium for Performance Improvement; ARB, angiote
EF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfun
*Test measures designated for use in internal quality improvement programs
rformance, physician ranking, or public reporting programs.ns, the writing committee reviewed other clinical guidance hocuments, as detailed below, as well as available information
gaps in care and unexplained variations in care for HF
tients. The writing committee also reviewed data on feasibil-
, reliability, and exception reporting available from implemen-
tion of a subset of the 2005 measures (28–30). The writing
mmittee applied a patient-centric approach to identify areas in
hich new measures or revisions to the 2005 measures might be
eded. As part of this process, the writing committee also
nsidered whether any of the 2005 measures should be retired.
fter extensive discussion and additional review of the litera-
re, consensus was reached on revisions to be made to the
easures included in the 2005 inpatient and outpatient measure
ts. All measures were designed to assess high-quality care in
propriate patients across a variety of care settings and care
ams and to support achievement of the identified desirable
tcomes. The measures were also designed to allow for the
clusion of patients with contraindications to the process of
re or other valid reasons for not being included in the measure.
defining the measure exclusions, the writing committee was
ided by the AMA-PCPI “Specification and Categorization of
easure Exclusions” (31).
The writing committee evaluated the potential new and
vised measures against the ACCF/AHA attributes of perfor-
ance measures (Table 7) to reach consensus on which mea-
res should advance for inclusion in the final measure set and
hether to designate any of the measures as test measures
ppropriate for internal quality improvement only) in the final
t. After the peer review and public comment period, the
riting committee reviewed and discussed the comments re-
ived and further refinements were made to the measure set.
. ACCF/AHA/AMA-PCPI
011 Performance Measures for
dults With Heart Failure
.1. Inpatient Target Population
nd Care Period
he target population for the inpatient measures consists of
ith HF Set: Dimensions of Care Outpatient Measures Matrix
Treatment Self-Management Monitoring of Disease Status
✓
✓
✓ ✓
✓
✓
✓
ng enzyme; AHA, American Heart Association; AMA-PCPI, American Medical
eceptor blocker; HF, heart failure; ICD, implantable cardioverter-defibrillator;
hese measures are not appropriate for any other use, for example, pay fordults W
cation
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May 15, 2012:1812–32 ACCF/AHA/AMA-PCPI Heart Failure Performance Measuresarge diagnosis of HF. The principal diagnosis is the
ndition established after study to be chiefly responsible for
e hospitalization. Detailed specifications, including excep-
ble 6. Comparison of 2005 and 2011 HF Performance Measure
11 Measure 2005 Measure C
patient measures
2. LVEF assessment
(inpatient setting)
Evaluation of left
ventricular systolic
function
● Added qua
description
equivalent
● Simplified
(medical r
examples)
6. Beta-blocker therapy
for LVSD (outpatient
and inpatient setting)
Beta-blocker therapy ● Added inp
2005 mea
blocker th
● Added spe
blockers (
carvedilol,
release m
succinate)
7. ACE inhibitor or ARB
therapy for LVSD
(outpatient and
inpatient setting)
ACE inhibitor or ARB
therapy for LVSD
● This meas
inpatient a
measures.
● Added defi
“prescribe
● Simplified
(medical r
examples,
with exam
reasons w
9. Postdischarge
appointment for
HF patients
No measure for 2005 This is a new
Anticoagulant at discharge
for HF patients with
atrial fibrillation
This measureon criteria, methods of reporting, and additional back- tround, are available on the AMA-PCPI Web site at http://
ww.ama-assn.org/apps/listserv/x-check/qmeasure.cgi?
bmitPCPI. For all inpatient measures, patients who were
Rationale
F
ns
with
Evaluation of LVEF in patients with HF provides important
information required to appropriately direct treatment.
● Qualitative LVEF equivalents provide additional
guidance to measure implementers and allow for
easier implementation of treatment-based measures.
● The ACCF/AHA/AMA-PCPI standard format for process
measure exceptions is to group them into medical,
patient, and system reasons with a limited number of
frequently occurring examples. This allows patients for
whom a test or treatment may not be appropriate to
be excluded from the denominator while allowing for
patient preferences and clinical judgment in
individualizing care.
tting to
beta-
ta
l,
ained-
l
erator.
● Combining measures allows harmonization of
specifications across settings.
● The 2009 ACCF/AHA guideline update has a Class I
recommendation for a beta blocker at discharge (19).
● Clinical trials indicate that the benefit of beta-blocker
therapy does not represent a class effect, and the
2009 ACCF/AHA guideline update recommends that
specific evidence-based beta blockers be
prescribed (19).
● In patients hospitalized with HF with reduced ejection
fraction not treated with oral therapies known to
improve outcomes, particularly ACE inhibitors or ARBs
and beta-blocker therapy, initiation of these therapies
is recommended in stable patients before hospital
discharge (19).
bines
atient
f
ns
with
reasons
d system
ples).
● Recent national registry data indicate that the use of
ACE inhibitors or ARBs in eligible patients without
documented contraindications or intolerance remains
suboptimal, especially in the outpatient setting.
● Combining measures allows harmonization of
specifications across settings.
● Addition of the definition of “prescribed” clarifies
which patients should be counted in the numerator.
● ACCF/AHA/AMA-PCPI standard format for process
measure exceptions is to group them into medical,
patient, and system reasons with a limited number of
frequently occurring examples. This allows patients for
whom a test or treatment may not be appropriate to
be excluded from the denominator while allowing for
patient preferences and clinical judgment in
individualizing care.
re.
tired. A similar measure has been developed for the broader
population of patients with atrial fibrillation and is
recommended for adoption in place of the previous
narrower version of this measure. The measure “Chronic
Anticoagulation Therapy” can be accessed on the AMA-
PCPI Web site under the Atrial Fibrillation and Atrial
Flutter project at http://www.ama-assn.org/ama1/pub/
upload/mm/pcpi/atrial-fib-flutter.pdf.
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erapy).
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11 Measure 2005 Measure Change Rationale
Discharge instructions This measure was retired. This measure addresses an important component of care
for the hospitalized patient, but its implementation in
practice seems to have resulted in improved compliance
without regard to the quality of discharge instructions
provided. Another measure, patient self-care education,
which addresses this important transition in care, has
been included as part of the current measure set and
was developed with the intent of having a greater impact
on morbidity and readmission.
Adult smoking cessation
advice/counseling
This measure was retired. A similar measure is available for a much broader
patient population and is recommended for adoption in
place of the previous narrower version of this measure.
The measure “Tobacco Use: Screening and Cessation
Intervention” can be accessed under the Preventive Care
and Screening project on the AMA-PCPI Web site at
http://www.ama-ssn.org/ama1/pub/upload/mm/370/pcs_
final08.pdf.
tpatient measures
1. LVEF assessment
(outpatient setting)
Left ventricular function
assessment
The description has been
modified.
Evaluation of LVEF in HF patients provides important
information required to direct appropriate treatment.
3. Symptom and
activity assessment
● Assessment of activity
level
● Assessment of clinical
symptoms of volume
overload
Both original measures were
combined into a single
measure.
This measure provides a more comprehensive
assessment of patient status. It improves on the previous
version of the measure(s) in that it requires a
quantitative assessment of a patient’s level of activity
and symptoms.
4. Symptom
management*
No measure for 2005 This is a new measure, to be
used as a quality metric.
Decreasing symptoms and improving function are 2 of
the primary goals of HF treatment. The results of an
ongoing assessment of patient symptoms serve as the
main basis for monitoring and titrating treatment
regimens.
5. Patient self-care
education*
Patient education This measure has changed to
a quality metric.
Although there has been research to support certain
educational components, the measure was based on
expert opinion. In addition, the writing committee was
concerned that compliance with the measure can be
achieved without regard to the quality of the education
provided.
6. Beta-blocker therapy
for LVSD (outpatient
and inpatient setting)
Beta-blocker therapy ● Added inpatient setting.
● Added specific beta
blockers (bisoprolol,
carvedilol, or sustained-
release metoprolol
succinate) to numerator.
Clinical trials indicate that the benefit of beta-blocker
therapy does not represent a class effect, and the 2009
ACCF/AHA guideline update recommends that specific
evidence-based beta blockers be prescribed (19).
7. ACE inhibitor or ARB
therapy for LVSD
(outpatient and
inpatient setting)
ACE inhibitor or ARB
therapy
Recent national registry data indicate that the use of ACE
inhibitors or ARBs in eligible patients without
documented contraindications or intolerance remains
suboptimal, especially in the outpatient setting (26).
8. Counseling about
ICD implantation for
patients with LVSD
combination medical
therapy*
No measure for 2005 This is a new measure, to be
used as a quality metric.
This measure is of value because ICDs have been proved
to be highly effective for preventing sudden death due to
ventricular tachyarrhythmias in a subset of HF patients.
Recent national registry data indicate that almost 50% of
eligible patients do not undergo implantation of an ICD or
a cardiac resynchronization therapy device with
defibrillation capabilities (26).
Initial laboratory tests This is a retired measure. Although recommended as a useful component in the
evaluation of HF patients, the measure assesses a
process that represents a standard of care. Performance
is believed to be high and the measure is not likely to
have a significant impact on care/improvement in
outcomes.
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May 15, 2012:1812–32 ACCF/AHA/AMA-PCPI Heart Failure Performance Measuresvice, were discharged to hospice, or died during the index
mission are excluded.
.2. Outpatient Target Population
nd Care Period
he target population for the outpatient measures consists of
tients aged 18 years with a diagnosis of HF. Detailed
ecifications, including exception criteria, methods of report-
g, and additional background, are available on the AMA-PCPI
eb site at http://www.ama-assn.org/apps/listserv/x-check/
easure.cgi?submitPCPI. For purposes of this document,
e outpatient care period is defined as the care provided in an
tpatient setting within the time period under evaluation
2-month reporting period).
.3. Data Collection
hese performance measures are ideally intended for pro-
ective use to enhance the quality improvement process but
ay also be applied retrospectively. The technical specifica-
ons for multiple data sources, including electronic health
cord data, electronic administrative data (claims), expanded
ultiple-source) administrative data, and paper medical
cord/retrospective data collection flow sheet can be found
ble 6. Continued
11 Measure 2005 Measure C
Weight measurement This is a reti
Blood pressure
measurement
This is a reti
Assessment of clinical
signs of volume overload
(excess)
This is a reti
Warfarin therapy for
patients with atrial
fibrillation
This is a reti
ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-
sociation–Physician Consortium for Performance Improvement; ARB, angioten
EF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfun
*Test measures designated for use in internal quality improvement programs
rformance, physician ranking, or public reporting programs.Appendix C. pr.4. Measure Exceptions and Challenges
Implementation
he writing committee added exclusion criteria, recognizing
at there are justifiable reasons for not meeting the perfor-
ance measures. Specific documentation of these measure
ceptions, which may be due to patient, medical, or system
asons, should be captured to provide data for future re-
arch and facilitate in-depth quality improvement in situa-
ons where there are apparent outliers with respect to the
mber of patients with exceptions.
. Discussion
he “ACCF/AHA/AMA-PCPI 2011 Performance Measures
r Adults With Heart Failure” addresses many of the same
ocesses of care as earlier measurement sets published by
e ACCF/AHA, the AMA-PCPI, and other organizations.
he writing committee has been cognizant of the previous
forts of other groups and sought to enhance and clarify
easures in ways that reflect the advancement of the under-
ing science, the complexity of care, and the challenges of
curate and complete data collection. In particular, the
Rationale
sure. Although recommended as a useful component in the
evaluation of HF patients, the supporting evidence is
poor (i.e., it is based only on expert opinion, case
studies, or standard of care) and does not meet the rigor
required for performance measurement. Performance is
high and the measure is not likely to have a significant
impact on care/improvement in outcomes.
sure. Although recommended as a useful component in the
evaluation of HF patients, the supporting evidence is
poor (i.e., it is based only on expert opinion, case
studies, or standard of care) and does not meet the rigor
required for performance measurement. Performance is
high and the measure is not likely to have a significant
impact on care/improvement in outcomes.
sure. Although recommended as a useful component in the
evaluation of HF patients, the supporting evidence is
poor (i.e., it is based only on expert opinion, case
studies, or standard of care) and does not meet the rigor
required for performance measurement.
sure. This measure is of value in improving quality of care for
HF patients with comorbid atrial fibrillation. A similar
measure has been developed for the broader population
of patients with atrial fibrillation and is recommended for
adoption in place of the previous narrower version of this
measure. The measure “Chronic Anticoagulation
Therapy” can be accessed on the AMA-PCPI Web site
under the Atrial Fibrillation and Atrial Flutter project at
http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/
atrial-fib-flutter.pdf.
ng enzyme; AHA, American Heart Association; AMA-PCPI, American Medical
ceptor blocker; HF, heart failure; ICD, implantable cardioverter-defibrillator;
hese measures are not appropriate for any other use, for example, pay forhange
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ACCF/AHA/AMA-PCPI Heart Failure Performance Measures May 15, 2012:1812–32veloped jointly by CMS and The Joint Commission for
anagement of patients with HF (33).
The writing committee recognizes that not all Class I
ideline recommendations lend themselves to the develop-
ent of excellent performance measures, because many do
t easily fit the attributes of performance measures in terms
usefulness, accuracy, feasibility, and measurability. Thus,
e writing committee selected only those Class I recommen-
tions that were considered to perform well as performance
easures in the inpatient or outpatient setting. In addition, in
e case of the angiotensin-converting enzyme (ACE) inhib-
or/angiotensin II receptor blocker (ARB) therapy measure, a
lass IIa guideline recommendation for the use of ARBs as
rst-line therapy was accepted by the committee, and the use
ARB therapy was considered equivalent to ACE inhibitor
erapy for this measure, which was also the case in the 2005
F performance measures (3). Although Class IIa recommen-
tions are not considered for stand-alone measures, in some
ses, such as this one, they provide additional information
out valid alternative therapies that are considered by the
mmittee for inclusion in a measure set. This exception is
ade so that physicians receive credit for prescribing or
ntinuing ARB therapy in HF patients who have left
ntricular systolic dysfunction.
The support for use of ARBs in patients with HF and
duced left ventricular ejection fraction has evolved signif-
antly in response to published clinical trials that showed
RBs to be an effective alternative therapy (34), and such use
recommended in the 2009 HF focused update (19) as a
asonable alternative therapy. Thus, the writing committee
ble 7. ACCF/AHA Attributes of Performance Measures
nsideration Attribute
eful in improving
tient outcomes
Evidence-based
Interpretable
Actionable
easure design Denominator precisely defined
Numerator precisely defined
Validity type
● Face*
● Content†
● Construct†
Reliability
easure
plementation
Feasibility
● Reasonable effort
● Reasonable cost
● Reasonable time period for collection
erall assessment Overall assessment of measure for inclusion
in measurement set
ACCF indicates the American College of Cardiology Foundation; AHA,
erican Heart Association.
*The measure intuitively seems to capture what it is intended to capture.
†The extent to which the items comprehensively capture the domain the
ms are intended to measure.
†The extent to which the measures correlate with other methods of
antifying the underlying construct.
Adapted from Normand et al (32) with permission of the publisher. Copyright
1998, International Society for Quality in Health Care.cided to continue the inclusion of ARB therapy in the ACE hohibitor measure for use in both the inpatient and outpatient
tting.
The inpatient and outpatient measures are designed to be
plemented in either a retrospective chart abstraction pro-
ss or they can be used as part of a prospective quality
provement process. The data collection tool suggested for
e with the inpatient measures (Appendix C) permits pro-
ective data capture as well and promotes the prospective
entification of HF patients. For example, documentation of
tient education is often difficult to obtain in retrospective
art review but can be easily implemented using a prospec-
ve patient management tool. These inpatient and outpatient
easures will require additional testing in practice to deter-
ine reliability and validity and may require modification in
e future.
The writing committee also deemed it important to add
clusion criteria to the measures to recognize that there are
stifiable medical and patient reasons for not meeting the
rformance measures. In the inpatient set, these reasons
ould be included in the “reasons documented by physician,
rse practitioner, or other healthcare provider for not .” In
e outpatient set, medical and patient reasons for not meeting
e measure are listed separately. Documentation of such
ctors should be encouraged and will provide valuable data
r future research and conducting in-depth quality improve-
ent for situations where there seem to be outliers with
spect to the number of patients with medical or patient-
ntered exclusions for the performance measures.
Challenges to implementation of measures are discussed
here applicable. In general, inadequate documentation is the
itial challenge of any measurement effort. The fact that
ese challenges are discussed is not intended as an argument
ainst measurement. Rather, they should be considered as
utionary notes that draw attention to areas where additional
cus on research and improvement of the measures should
considered.
The 2011 HF performance measures address processes of
re. The writing committee did not develop measures of
tient outcome in terms of mortality or repeat hospitalization
cause these outcome measures are already in place and
blicly reported by CMS. The new measure of symptom
anagement does address one component of outcome and
lls for a plan of action if patient status has not improved or
s deteriorated.
.1. Major Revisions to the
005 Heart Failure Measures
.1.1. Retirement of Performance Measures
ight measures in the 2005 HF performance measures (3)
ere retired in the present measure set (Table 6). The
easure on anticoagulation therapy for patients with HF and
rial fibrillation was retired from the inpatient and outpatient
easures because a similar measure has been developed for
e broader population of patients with atrial fibrillation (12)
d is recommended for adoption in place of the previous
rrower version of this measure. The measure on discharge
structions addressed an important component of care for the
spitalized patient, but its implementation in practice seems
to
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May 15, 2012:1812–32 ACCF/AHA/AMA-PCPI Heart Failure Performance Measureshave resulted in improved compliance without regard to
e quality of discharge instructions provided. Another mea-
re that addresses the important transition from inpatient to
tpatient care has been included as part of the present
easure set (9. Postdischarge appointment for HF patients)
d was developed with the intent of having a greater impact
morbidity and readmission. The measure on smoking
ssation advice/counseling was retired, because a similar
easure has been developed for a much broader patient
pulation. The measure “Tobacco Use: Screening and Ces-
tion Intervention” can be accessed under the Preventive
are & Screening project on the AMA-PCPI Web site at
ttp://www.ama-assn.org/ama1/pub/upload/mm/370/
s_final08.pdf and is recommended for adoption in place of
e previous narrower measure. The outpatient measures on
itial laboratory testing, weight measurement, and blood
essure measurement were retired because they represent
andards of care, performance is believed to be high, and the
easures are not likely to have a significant impact on care or
provement in outcomes. Finally, the measure on assessment
signs of volume overload was retired because the supporting
idence is not strong and does not meet the rigorous standard
w required for performance measurement.
.1.2. Expansion of Beta-Blocker Measure to
patient Setting
eta-blocker therapy for patients with HF and left ventricular
stolic dysfunction was an outpatient measure in the 2005
F performance measures (3). Although a measure for
patient treatment with beta blockers was considered at that
me, no inpatient measure was developed because there was
specific guideline recommendation for the use of beta
ockers in the inpatient setting in 2005. In response to the
w Class I recommendation for beta-blocker therapy at
scharge in the 2009 HF focused update (19), the beta-
ocker measure has been expanded in the current perfor-
ance measures to include both outpatient and inpatient
ttings. In addition, clinical trial data indicate that the benefit
beta-blocker therapy does not appear to represent a class
fect, and the 2009 HF focused update recommends that
ecific beta blockers be prescribed (19). Thus, the revised
easure specifies 1 of 3 evidence-based beta blockers (biso-
olol, carvedilol, or sustained-release metoprolol succinate)
the numerator.
It should be emphasized that in-hospital initiation of beta
ockers is recommended only in stable patients before
spital discharge (19). Regardless of the severity of symp-
ms, patients should not be hospitalized in an intensive care
it, should have no or minimal evidence of fluid overload or
lume depletion, and should not have required recent
eatment with an intravenous positive inotropic agent.
.1.3. New Performance Measure:
ymptom Management
ymptom assessment remains an important component of
ery encounter with a patient with HF. However, symptom
sessment alone is insufficient in patients whose symptoms
e progressive or poorly controlled. Hence, the writing
mmittee developed a new measure on symptom manage-
ent that can be paired with the measure on symptom wsessment. The symptom management measure includes
cumentation of a care plan to attempt to alleviate ongoing
mptoms by changing medication doses, adding new medi-
tions, considering device therapy, or referring patients to
ecialty HF teams for advanced care.
.1.4. Changed to Quality Metric: Patient Education
atient education about lifestyle, physical activity, diet, and
edications is an important component of providing quality
re for patients with HF. However, whether documentation
patient education in the medical record improves outcomes
uncertain. Compliance with a measure of patient education
relatively easy to achieve without regard to the quality of
tual education provided. For this reason, the patient educa-
on measure was changed from a performance measure
commended for public reporting to a quality metric for
ternal quality improvement.
.1.5. New Quality Metric: Counseling About
plantable Cardioverter-Defibrillators
he writing committee considered a measure for implantation
an implantable cardioverter-defibrillator for the reduction
occurrence of sudden death in patients with severe left
ntricular systolic dysfunction. Such a measure was not
veloped because of concerns related to the large number of
ceptions due to patient factors (age, comorbidities, patient
eference) and physician factors. Rather, the writing com-
ittee developed a measure to address counseling about the
tential benefits of implantable cardioverter-defibrillators in
propriately selected patients instead of the actual implan-
tion itself.
.2. Potential Measures Considered
ut Not Included in This Set
he writing committee considered including a composite
easure of the prescription of both ACE inhibitor and
ta-blocker therapy. The complexities of developing and
plementing such an “all or none” optimal medical therapy
easure (35) became clear during the public comment and
er review processes and led the writing committee to
velop separate ACE inhibitor and beta-blocker measures
at could be used as paired measures instead of a single
mposite measure.
Two other measures were developed by the writing com-
ittee but ultimately removed from the HF performance
easure set after the peer review and public comment
riods. These were the “Overuse of Echocardiography”
easure from the outpatient set and “End-of-Life Care Plan”
easure from the inpatient set. These measures, although
tentially of value for improving patterns of care, were not
lt to have been tested in clinical situations to ensure their
liability and validity. The writing committee notes 2
oader measures that address the provision of palliative care
d end-of-life care and are intended for use in eligible
tients with HF. One measure jointly developed by the
MA-PCPI and the National Committee for Quality Assur-
ce, “Advance Care Planning,” can be accessed under the
alliative Care project on the AMA-PCPI Web site at http://
ww.ama-assn.org/ama1/pub/upload/mm/pcpi/palliative-care.pdf.
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eriatrics Society, and National Committee for Quality
ssurance that has been targeted to a broader patient popu-
tion, “Advance Care Plan,” can be accessed under the
eriatrics project on the AMA-PCPI Web site at http://
ww.ama-assn.org/ama1/pub/upload/mm/pcpi/geriatrics-
s.pdf.
The writing committee considered a number of additional
tential measures that focus on equally important aspects of
re, but after extensive discussion, the committee declined to
velop these measures either because of an anticipated large
mber of exclusions in the denominator or because of
allenges in implementation. Such is the case for cardiac
synchronization therapy, in which methods to predict which
tients will derive improved outcomes remain imperfect and
e identification of all patients with prolonged QRS com-
exes, who would constitute the denominator, would be a
asibility challenge. Another measure related to treatment
ith aldosterone receptor antagonists was considered but
t developed because of the large number of patients
cluded from the denominator because of renal insuffi-
ency or hyperkalemia before or during treatment with
ese agents. In addition, the development of serious renal
ilure or hyperkalemia in large numbers of patients might
an unintended consequence of the broad implementa-
on of such a measure. Finally, treatment with combined
dralazine and nitrate therapy for black patients with HF
as also considered but not developed. Although this
erapy has been shown to be efficacious in blacks,
fining the denominator would be difficult or impossible
r most practices. If future methods to collect information
race/ethnicity are determined to be reliable, this barrier
measurement may be overcome.
. Conclusions
he “2005 ACC/AHA Heart Failure Performance Measures”
) were well aligned with the HF measures of the CMS and
he Joint Commission. The ACCF, AHA, and AMA-PCPI
ill continue to work with the CMS, The Joint Commission,
d the National Quality Forum to harmonize measures for
re of patients with HF.
To be successful as quality improvement tools, these 9
easures in the current HF performance measure set need to
adopted, implemented, and integrated as routine compo-
nts of patient care across various care settings. These
easurement sets should contribute to the evolution of
porting systems that allow physicians and other health-
re providers to improve care for a critical patient
pulation. Quality improvement is a continuous process,
d this document reflects the lessons the practicing
mmunity has learned to date in using existing measures
d knowledge gained about how these measures might be
proved. The clinical care team should collect data and
view adherence to these measures on a routine basis,
ok for changes, and adjust practice patterns as needed to
prove performance.taff
merican College of Cardiology Foundation
avid R. Holmes, Jr, MD, FACC, President
hn C. Lewin, MD, Chief Executive Officer
illiam Oetgen, MD, MBA, FACC, FACP, Senior Vice
President, Science and Quality
harlene May, Senior Director, Science and Clinical Policy
elanie Shahriary, RN, BSN, Director, Performance Measures
and Data Standards
merican College of Cardiology Foundation/
merican Heart Association
nsen S. Chiu, MHA, Specialist, Clinical Performance
Measures
merican Heart Association
ordon Tomaselli, MD, FACC, FAHA, President
ancy Brown, Chief Executive Officer
ose Marie Robertson, MD, FACC, FAHA, Chief Science
Officer
ayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice
President, Office of Science Operations
ark D. Stewart, MPH, Science and Medicine Advisor,
Office of Science Operations
heryl L. Perkins, MD, RPh, Science and Medicine Advisor,
Office of Science Operations
dy Hundley, Production Manager, Scientific Publications,
Office of Science Operations
merican Medical Association-
hysician Consortium for Performance
provement
ark Antman, DDS, MBA, Director, Measure Development
Operations
endra Hanley, MS, Project Manager II, Measure Specifica-
tions, Standards, and Informatics
eAnn Jackson, MJ, Senior Policy Analyst II, AMA-PCPI
Operations
aren Kmetik, PhD, Vice President, Performance Improvement
amela O’Neil, MPH, Senior Policy Analyst I, Measure
Development Operations
arjorie Rallins, DPM, Director, Measure Specifications,
Standards, and Informatics
amantha Tierney, MPH, Project Manager II, Measure
Development Operations
regory Wozniak, PhD, Director, Measure Analytics and
Economic Evaluation
R
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1825JACC Vol. 59, No. 20, 2012 Bonow et al.
May 15, 2012:1812–32 ACCF/AHA/AMA-PCPI Heart Failure Performance Measureseferences
. Committee on Quality of Health Care in America, Institute of Medicine.
Crossing the Quality Chasm: A New Health System for the 21st Century.
Washington, DC: National Academy Press; 2001.
. Spertus JA, Eagle KA, Krumholz HM, Mitchell KR, Normand SL.
American College of Cardiology and American Heart Association meth-
odology for the selection and creation of performance measures for
quantifying the quality of cardiovascular care. J Am Coll Cardiol.
2005;45:1147–56.
. Bonow RO, Bennett S, Casey DE Jr., et al. ACC/AHA clinical perfor-
mance measures for adults with chronic heart failure: a report of the
American College of Cardiology/American Heart Association Task Force
on Performance Measures (Writing Committee to Develop Heart Failure
Clinical Performance Measures). J Am Coll Cardiol. 2005;46:1144–78.
. American College of Cardiology Foundation/American Heart Associa-
tion/American Medical Association–Physician Consortium for Perfor-
mance Improvement. Heart failure performance measurement set. Avail-
able at: http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/hfset-12-
5.pdf. American Medical Association. Accessed August 24, 2011.
. American College of Cardiology Foundation/American Heart Associa-
tion/American Medical Association–Physician Consortium for Perfor-
mance. Chronic stable coronary artery disease performance measurement
set. Chicago, IL: American Medical Association; 2005.
. Drozda J Jr., Messer JV, Spertus J, et al. ACCF/AHA/AMA-PCPI 2011
performance measures for adults with coronary artery disease and
hypertension: a report of the American College of Cardiology Founda-
tion/American Heart Association Task Force on Performance Measures
and the American Medical Association–Physician Consortium for Per-
formance Improvement. J Am Coll Cardiol. 2011;58:316–36.
. American College of Cardiology Foundation/American Heart Associa-
tion/American Medical Association–Physician Consortium for Perfor-
mance Improvement. Hypertension performance measurement set. Chi-
cago, IL: American Medical Association; 2005.
. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical
performance measures for adults with ST-elevation and non-ST-elevation
myocardial infarction: a report of the American College of Cardiology/
American Heart Association Task Force on Performance Measures
(Writing Committee to Develop Performance Measures on ST-Elevation
and Non-ST-Elevation Myocardial Infarction) [published correction ap-
pears in J Am Coll Cardiol. 2006;47:2140]. J Am Coll Cardiol. 2006;47:
236–65.
. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008
performance measures for adults with ST-elevation and non-ST-elevation
myocardial infarction: a report of the American College of Cardiology/
American Heart Association Task Force on Performance Measures
(Writing Committee to Develop Performance Measures for ST-Elevation
and Non-ST-Elevation Myocardial Infarction) [published correction ap-
pears in J Am Coll Cardiol. 2011;57:637–9]. J Am Coll Cardiol.
2008;52:2046–99.
. Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007 perfor-
mance measures on cardiac rehabilitation for referral to and delivery of
cardiac rehabilitation/secondary prevention services. J Am Coll Cardiol.
2007;50:1400–33.
. Thomas RJ, King M, Lui K, et al. AACVPR/ACCF/AHA 2010 update:
performance measures on cardiac rehabilitation for referral to cardiac
rehabilitation/secondary prevention services: a report of the American
Association of Cardiovascular and Pulmonary Rehabilitation and the
American College of Cardiology Foundation/American Heart Association
Task Force on Performance Measures (Writing Committee to Develop
Clinical Performance Measures for Cardiac Rehabilitation). J Am Coll
Cardiol. 2010;56:1159–67.
. Estes NA 3rd, Halperin JL, Calkins H, et al. ACC/AHA/Physician
Consortium 2008 clinical performance measures for adults with nonval-
vular atrial fibrillation or atrial flutter: a report of the American College
of Cardiology/American Heart Association Task Force on Performance
Measures and the Physician Consortium for Performance Improvement
(Writing Committee to Develop Clinical Performance Measures for Atrial
Fibrillation). J Am Coll Cardiol. 2008;51:865–84.
. Redberg RF, Benjamin EJ, Bittner V, et al. AHA/ACCF [corrected] 2009
performance measures for primary prevention of cardiovascular disease
in adults: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Performance Measures
(Writing Committee to Develop Performance Measures for PrimaryPrevention of Cardiovascular Disease) [published correction appears in
Circulation. 2010:121:e445–6]. Circulation. 2009;120:1296–336.
. Olin JW, Allie DE, Belkin M, et al. ACCF/AHA/ACR/SCAI/SIR/SVM/
SVN/SVS 2010 performance measures for adults with peripheral artery
disease: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Performance Measures, the
American College of Radiology, the Society for Cardiac Angiography
and Interventions, the Society for Interventional Radiology, the Society
for Vascular Medicine, the Society for Vascular Nursing, and the Society
for Vascular Surgery (Writing Committee to Develop Clinical Perfor-
mance Measures for Peripheral Artery Disease). J Am Coll Cardiol.
2010;56:2147–81.
. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical
models used for public reporting of health outcomes: an American Heart
Association scientific statement from the Quality of Care and Outcomes
Research Interdisciplinary Writing Group: cosponsored by the Council on
Epidemiology and Prevention and the Stroke Council. J Am Coll Cardiol.
2010;56:2147–81.
. Spertus JA, Bonow RO, Chan P, et al. ACCF/AHA new insights into the
methodology of performance measurement: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Performance Measures. J Am Coll Cardiol. 2010;56:1767–82.
. American Medical Association. PCPI work group charge. Available at:
http://www.ama-assn.org/resources/doc/cqi/pcpi-work-group-charge.pdf.
Accessed August 24, 2011.
. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline
update for the diagnosis and management of chronic heart failure in the
adult: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Committee to
Update the 2001 Guidelines for the Evaluation and Management of Heart
Failure) [published correction appears in J Am Coll Cardiol. 2006;47:
1503–5]. J Am Coll Cardiol 2005;46:e1–82.
. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorpo-
rated into the ACC/AHA 2005 guidelines for the diagnosis and manage-
ment of heart failure in adults: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on Prac-
tice Guidelines [published correction appears in J Am Coll Cardiol.
2009;54:2464]. J Am Coll Cardiol. 2009;53:e1–90.
. Physician Consortium for Performance Improvement (PCPI) position
statement: the evidence base required for measures development. Avail-
able at: http://www.ama-assn.org/ama1/pub/upload/mm/370/pcpi-
evidence-based-statement.pdf. Accessed August 2, 2010.
. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008
guidelines for device-based therapy of cardiac rhythm abnormalities:
executive summary: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Writing
Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for
Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) [pub-
lished corrections appear in J Am Coll Cardiol. 2009;53:147; J Am Coll
Cardiol. 2009;53:1473]. J Am Coll Cardiol. 2008;51:e1–62.
. Adams KF, Lindenfeld J, Arnold JMO, et al. HFSA 2006 comprehensive
heart failure practice guideline. J Card Fail. 2006;12:e1–122.
. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive
heart failure practice guideline. J Card Fail. 2010;16:e1–194.
. Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to
improve the palliative care of pain, dyspnea, and depression at the end of
life: a clinical practice guideline from the American College of Physi-
cians. Ann Intern Med. 2008;148:141–6.
. Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/
ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transtho-
racic and transesophageal echocardiography: a report of the American
College of Cardiology Foundation Quality Strategic Directions Commit-
tee Appropriateness Criteria Working Group, American Society of
Echocardiography, American College of Emergency Physicians, Ameri-
can Society of Nuclear Cardiology, Society for Cardiovascular Angiog-
raphy and Interventions, Society of Cardiovascular Computed Tomogra-
phy, and the Society for Cardiovascular Magnetic Resonance. J Am Coll
Cardiol. 2007;50:187–204.
. Fonarow GC, Yancy CW, Albert NM, et al. Heart failure care in the
outpatient cardiology practice setting: findings from IMPROVE HF. Circ
Heart Fail. 2008;1:98–106.
. McGlynn E, Asch SM, Adams J, et al. The quality of health care delivered
to adults in the United States. N Engl J Med. 2003;348:2635–45.
. Centers for Medicare and Medicaid Services, Department of Health and
Human Services. DOQ and DOQ-IT measure specifications. Available at:
29
30
31
32
33
34
35
K
qu
1826 Bonow et al. JACC Vol. 59, No. 20, 2012
ACCF/AHA/AMA-PCPI Heart Failure Performance Measures May 15, 2012:1812–32http://www.qualitynet.org/dcs/ContentServer?cid1143577171055
&pagenameQnetPublic%2FPage%2FQnetTier2&cPage. Accessed
August 24, 2011.
. American Medical Association. Cardio-Hit Phase II. Available at: http://
images.ahrq.gov/publishedimages/communities/a_e/ahrq_funded_
projects/projects/calendaryearupdates/cardio_hit_phase_ii___
2009html_2.htm. Accessed February 6, 2012.
. Baker DW, Persell SD, Thompson JA, et al. Automated review of
electronic health records to assess quality of care for outpatients with
heart failure. Ann Intern Med. 2007;146:270–7.
. Physician Consortium for Performance Improvement (PCPI) position
statement: specification and categorization of measure exclusions: rec-
ommendations to PCPI work groups. Available at: http://www.
ama-assn.org/resources/doc/cqi/exclusions053008.pdf. American Medi-
cal Association. Accessed August 24, 2011.
. Normand SL, McNeil BJ, Peterson LE, Palmer RH. Eliciting expert
opinion using the Delphi technique: identifying performance indicators
for cardiovascular disease. Int J Qual Health Care. 1998;10:247–60. le. The Joint Commission. Specifications Manual for National Hospital
Quality Measures Version 1.02: Measure Information Forms–Heart
Failure (HF). Available at: http://www.qualitynet.org/dcs/Content
Server?cPage&pagenameQnetPublic%2FPage%2FQnetTier4&cid
1141662780107. Accessed February 29, 2012.
. McClellan MB, Loeb JM, Clancy CM, et al. Angiotensin-converting
enzyme inhibitors and angiotensin-receptor blockers in chronic heart
failure. Ann Intern Med. 2005;142:386–7.
. Peterson ED, DeLong ER, Masoudi FA, et al. ACCF/AHA 2010 position
statement on composite measures for healthcare performance assessment:
a report of the American College of Cardiology Foundation/American
Heart Association Task Force on Performance Measures (Writing Com-
mittee to Develop a Position Statement on Composite Measures). J Am
Coll Cardiol. 2010;55:1755–66.
ey Words: ACCF/AHA Performance Measures  ambulatory-level
ality  health policy and outcome research  heart failure  hospitalvel quality  quality indicators.
A
A
Ro
Co
Th
Co
Cr
Ka
Do
Sa
Ka
Ra
Ma
Th
Fre
Da
Ile
Pa
La
Jo
1827JACC Vol. 59, No. 20, 2012 Bonow et al.
May 15, 2012:1812–32 ACCF/AHA/AMA-PCPI Heart Failure Performance Measuresppendix A. Author Relationships With Industry and Other Entities—ACCF/AHA/AMA-PCPI 2011 Performance Measures for
dults With Heart Failure
Name Employment Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational, or
Other Financial
Benefit
Expert
Witness
bert O. Bonow,
-Chair
Northwestern University
Feinberg School of
Medicine—Goldberg
Distinguished Professor of
Cardiology
None None None None None None
eodore G. Ganiats,
-Chair
UCSD School of Medicine—
Professor and Interim Chair,
Department of Family and
Preventive Medicine
None None None None None None
aig T. Beam Medical Development
Specialists—Senior Vice
President
None None None None None None
thleen Blake Center for Medical
Technology Policy—Senior
Research Director; New
Mexico Heart Institute—
Physician
None None None None None None
nald E. Casey, Jr Atlantic Health—Vice
President of Quality and
Chief Medical Officer
None None None None None None
rah J. Goodlin Portland VAMC, Portland,
Oregon—Chief, Geriatrics
and Patient-Centered
Education and Research—
President
None None None ● Boston
Scientific
Corporation*
None None
thleen L. Grady Northwestern University
Feinberg School of
Medicine—Associate
Professor of Surgery and
Northwestern University
Center for Heart Failure
Bluhm Cardiovascular
Institute—Administrative
Director, Division of Cardiac
Surgery
None None None None None None
ndal F. Hundley Arkansas Health Group—
Medical Director
None None None None None None
riell Jessup University of Pennsylvania—
Professor of Medicine
● Boston Scientific
● Medtronic, Inc.
● Scios Inc.†
None None None None None
omas E. Lynn Ingenix—Senior Medical
Director, Clinical
Informatics*
None None None None ● Ingenix* None
derick A. Masoudi University of Colorado,
Denver—Associate
Professor of Medicine,
Division of Cardiology
● Amgen Inc.† None None None None None
vid Nilasena Centers for Medicare and
Medicaid Services—Chief
Medical Officer, Region VI
None None None None ● Roche
Diagnostics
Corporation
(spouse)*
None
ana L. Piña Albert Einstein College of
Medicine—Professor of
Medicine and Epidemiology
and Population Health;
Associate Chief for
Academic Affairs, Division of
Cardiology
● Astra Zeneca LP
● Merck & Co., Inc.
● Novartis
Pharmaceuticals
Corporation
● sanofi-aventis US, Inc.
● Solvay
None None None None None
ul D. Rockswold US Navy—Captain, Medical
Corps; Uniformed Services
University of the Health
Sciences—Adjunct Assistant
Professor, Preventive
Medicine and Biometrics†
None None None None None None
wrence B. Sadwin Torbot Group, Inc. None None None None None None
anna D. Sikkema University of Miami School
of Nursing and Health
Studies—Director of Acute
Care Nurse Practitioner
Program
None None None None None None
(Continued)
ACa
Jo
Pa
Eli
Ma
Jo
re
ow
fu
it
Re
Af
1828 Bonow et al. JACC Vol. 59, No. 20, 2012
ACCF/AHA/AMA-PCPI Heart Failure Performance Measures May 15, 2012:1812–32ppendix A. Continued
Name Employment Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational, or
Other Financial
Benefit
Expert
Witness
rrie A. Sincak Midwestern University
Chicago College of
Pharmacy—Associate
Professor and Vice Chair of
Acute Care, Department of
Pharmacy Practice
None None None None None None
hn Spertus Saint Luke’s Hospital of
Kansas City—Clinical
Director, Outcomes
Research
● Amgen Inc.
● Novartis
Pharmaceuticals
Corporation
● St. Jude Medical
● UnitedHealth
None ● Kansas City
Cardiomyopathy
Questionnaire*
● Peripheral
Artery
Questionnaire*
● Seattle Angina
Questionnaire*
● Amgen Inc.*
● Bristol-Myers
Squibb/Sanofi
Pharmaceuticals
Partnership*
● Eli Lilly and
Company*
● Johnson &
Johnson*
● Roche
Diagnostics
Corporation*
None None
trick J. Torcson St. Tammany Parish
Hospital—Director of
Hospital Medicine
None None None None None None
zabeth Torres Practicing physician None None None None None None
rk V. Williams Northwestern University
Feinberg School of
Medicine—Professor and
Chief, Division of Hospital
Medicine
None None None None None None
hn B. Wong Tufts Medical Center—
Chief, Division of Clinical
Decision Making
None None None None None None
This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be
levant to this document, at the time this document was under development. A person is deemed to have a significant interest in a business if the interest represents
nership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity; or if
nds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if
is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purposes of transparency.
lationships in this table are modest unless otherwise noted.
*Significant relationship.
†No financial relationship.
†The findings and conclusions of this report are those of the author(s) and do not necessarily represent the official positions of the US Navy or USUHS.
UCSD indicates University of California, San Diego; USUHS, Uniformed Services University of the Health Sciences; and VAMC, US Department of Veterans
fairs–Medical Center.
A
A
Ka
Gr
Ro
Eri
Ja
Je
Cr
Bib
Le
Ju
Da
An
Ba
1829JACC Vol. 59, No. 20, 2012 Bonow et al.
May 15, 2012:1812–32 ACCF/AHA/AMA-PCPI Heart Failure Performance Measuresppendix B. Reviewer Relationships With Industry and Other Entities—ACCF/AHA/AMA-PCPI 2011 Performance Measures for
dults With Heart Failure
Peer Reviewer Representation Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational, or
Other Financial
Benefit Expert Witness
thleen A. Dracup Official Reviewer—AHA None None None None None None
egg C. Fonarow Official Reviewer—AHA ● Abbott Laboratories†
● AstraZeneca LP
● Bristol-Myers
Squibb/Sanofi
Pharmaceuticals
Partnership†
● GlaxoSmithKline†
● Medtronic, Inc.†
● Merck/Schering-
Plough†
● Novartis
Pharmaceuticals
Corporation†
● Pfizer, Inc.
● Scios Inc.
None None ● GlaxoSmithKline†
● Medtronic, Inc.†
None None
bert Hobbs Official Reviewer—ACCF
Board of Governors
● Hospira ● Scios Inc. None None None None
c D. Peterson Official Reviewer—ACCF/
AHA Task Force on
Performance Measures
Lead Reviewer
● Eli Lilly and
Company
None None ● Bristol-Myers
Squibb/Sanofi
Pharmaceuticals
Partnership†
None None
mes E. Udelson Official Reviewer—ACCF
Board of Trustees
● Acusphere
● Boehringer-Ingelheim
Corporation
● Cytori Therapeutics
● GE Healthcare
● King
Pharmaceuticals,
Inc.
None None ● Baxter
● GlaxoSmithKline†
● Medtronic, Inc.
None None
ffrey L. Anderson Content
Reviewer—ACCF/AHA
Task Force on Practice
Guidelines
● Bristol Myers
Squibb/Sanofi
Pharmaceuticals
Partnership
● Daiichi-Sankyo, Inc.
● Eli Lilly and
Company
● sanofi-aventis
● Merck &
Co., Inc.
● Schering-
Plough
Corporation
None ● AstraZeneca LP None ● Defendant, COX-2,
2008
aig Clark Content Reviewer—ACCF
Board of Governors
● Forest
Pharmaceuticals
None None None None None
iana Cujec Content Reviewer—ACCF
Board of Governors
None None None None None None
e A. Green Content
Reviewer—ACCF/AHA
Task Force on
Performance Measures
None None None None None None
dith S. Hochman Content
Reviewer—ACCF/AHA
Task Force on Practice
Guidelines
● Eli Lilly and
Company
● Millennium
Pharmaceuticals,
Inc.
● Schering Plough
Research Institute
None None None ● GlaxoSmithKline None
vid E. Lanfear Content Reviewer—ACCF
Heart Failure and
Transplantation
Committee
None ● Thoratec None ● Merck & Co.,
Inc.*
● Johnson &
Johnson*
● sanofi-aventis*
None None
n Loth Content
Reviewer—ACCF/AHA
Task Force on
Performance Measures
None None None None None None
rry M. Massie Content Reviewer—ACCF
Heart Failure and
Transplantation
Committee
● Bristol-Myers Squibb
Company†
● Cytokinetics
● GlaxoSmithKline
● Merck & Co., Inc.
● Novartis
Pharmaceuticals
Corporation
None None None None None
(Continued)
AWa
Pa
Mi
Ly
Ste
Wi
Ste
re
m
pe
un
m
1830 Bonow et al. JACC Vol. 59, No. 20, 2012
ACCF/AHA/AMA-PCPI Heart Failure Performance Measures May 15, 2012:1812–32ppendix B. Continued
Peer Reviewer Representation Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational, or
Other Financial
Benefit Expert Witness
yne L. Miller Content Reviewer—ACCF
Heart Failure and
Transplantation
Committee
None None None None None None
sala Ravichandran Content Reviewer—ACCF
Heart Failure and
Transplantation
Committee
None None None None None None
chael W. Rich Content
Reviewer—Individual
None None None None None None
nne Warner
venson
Content
Reviewer—ACCF/AHA
Heart Failure Guideline
Writing Committee
None None None ● CardioMEMS
● Medtronic, Inc.
None ● CardioMEMS
● Medtronic, Inc.
lliam G.
venson
Content
Reviewer—ACCF/AHA
Task Force on Practice
Guidelines
● Biosense Webster
● Boston Scientific
Corporation
● Medtronic, Inc.
● St. Jude Medical,
Inc.
None None None None None
This table represents the relevant relationships with industry and other entities that were disclosed at the time of peer review. It does not necessarily reflect
lationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or
ore of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity, or if funds received by the
rson from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant
der the preceding definition. Relationships that exist with no financial benefit are also included for the purposes of transparency. Relationships in this table are
odest unless otherwise noted.
*Significant relationship.
†No financial relationship.ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; CV, cardiovascular; and GE, General Electric.
A
Pe
1831JACC Vol. 59, No. 20, 2012 Bonow et al.
May 15, 2012:1812–32 ACCF/AHA/AMA-PCPI Heart Failure Performance Measuresppendix C. American College of Cardiology Foundation, American Heart Association, and Physician Consortium for
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Provider No. _______________ Patient Name or Code ________________________________________ Birth Date ____/____/____ Sex □ M □ F 
                          (mm/dd/yyyy) 
Cl
in
ica
l A
ss
es
sm
en
t a
nd
 E
va
lu
at
io
n 
Left Ventricular Ejection Fraction (LVEF) Results                                                             
Date of Assessment:   ____/____/_____  
Instructions: Must include documentation of the quantitative or qualitative results of an LVEF assessment, regardless of when the evaluation of
ejection fraction was performed (ie, recent or prior [any time in the past]).                               
DATE OF VISIT 
(mm/dd/yyyy) ______/______/_____ ______/______/_____ ______/______/_____ ______/______/_____ 
Assessment of symptoms 
and activity by New York 
Heart Association (NYHA) 
classification or patient-
reported questionnaire1
NYHA:  I  /  II  /  III  /  IV 
KCCQ:  ________ (score) 
MLHFQ:  _______ (score) 
CHFQ:  ________ (score) 
 Other:  ________ (score) 
___Not assessed 
      (medical reasons*)   
NYHA:  I  /  II  /  III  /  IV 
KCCQ:  ________ (score) 
MLHFQ:  _______ (score) 
CHFQ:  ________ (score) 
Other:  ________ (score) 
___Not assessed 
(medical reasons*)   
NYHA:  I  /  II  /  III  /  IV 
KCCQ:  ________ (score) 
MLHFQ:  _______ (score) 
CHFQ:  ________ (score) 
Other:  ________ (score) 
___Not assessed 
      (medical reasons*)   
NYHA:  I  /  II  /  III  /  IV 
KCCQ:  ________ (score) 
MLHFQ:  _______ (score) 
CHFQ:  ________ (score) 
Other:  ________ (score) 
___Not assessed 
      (medical reasons*)   
Allergies, Adverse Drug 
Reactions
_____________________________
_____________________________
_____________________________
_____________________________
S y
m
pt
om
 M
an
ag
em
en
t 
Symptom management 
(Quality improvement only)
___Symptoms improved  
      since last visit or  
      remained consistent  
      with treatment goals   
___Symptoms improved  
      since last visit or  
      remained consistent  
      with treatment goals   
___Symptoms improved  
      since last visit or  
      remained consistent  
      with treatment goals   
___Symptoms improved  
      since last visit or  
      remained consistent  
      with treatment goals   
___Symptoms worsened2
      since last visit 
Plan of care to address 
symptom worsening3
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________ 
___Symptoms worsened2
      since last visit 
Plan of care to address 
symptom worsening3
______________________
______________________
______________________
______________________
______________________
______________________
______________________
______________________ 
___Symptoms worsened2
      since last visit 
Plan of care to address 
symptom worsening3
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________ 
___Symptoms worsened2
      since last visit 
Plan of care to address 
symptom worsening3
______________________
______________________
______________________
______________________
______________________
______________________
______________________
______________________ 
Me
di
ca
tio
n 
Ma
na
ge
m
en
t f
or
 P
at
ien
ts
 W
ith
 L
VS
D 
DATE OF VISIT 
(mm/dd/yyyy) ______/______/_____ ______/______/_____ ______/______/_____ ______/______/_____ 
Beta-blocker therapy for 
left ventricular systolic 
dysfunction (LVSD) 
(ie, bisoprolol, carvedilol, or 
sustained-release 
metoprolol succinate)
___Prescribed 
___Not prescribed
(medical reasons*) 
___Not prescribed  
      (patient reasons*) 
___Not prescribed
      (system reasons*) 
___Prescribed 
___Not prescribed
(medical reasons*) 
___Not prescribed  
      (patient reasons*) 
___Not prescribed
      (system reasons*)
___Prescribed 
___Not prescribed  
      (medical reasons*) 
___Not prescribed 
      (patient reasons*) 
___Not prescribed            
      (system reasons*) 
___Prescribed 
___Not prescribed  
      (medical reasons*) 
___Not prescribed 
      (patient reasons*) 
___Not prescribed            
      (system reasons*) 
ACE inhibitor or ARB 
therapy for LVSD 
___Prescribed 
___Not prescribed
(medical reasons*) 
___Not prescribed  
      (patient reasons*) 
___Not prescribed
(system reasons*)
___Prescribed 
___Not prescribed
(medical reasons*) 
___Not prescribed  
      (patient reasons*) 
___Not prescribed
      (system reasons*)
___Prescribed 
___Not prescribed  
      (medical reasons*) 
___Not prescribed  
      (patient reasons*) 
___Not prescribed            
      (system reasons*) 
___Prescribed 
___Not prescribed  
      (medical reasons*) 
___Not prescribed 
      (patient reasons*) 
___Not prescribed            
      (system reasons*) 
Counseling about 
implantable cardioverter-
defibrillator (ICD) 
implantation 
(Quality improvement only)
□ LVEF ≤35% 
□ Angiotensin-converting 
enzyme (ACE) 
inhibitor/angiotensin II 
receptor blocker (ARB) and 
beta-blocker therapy for at 
least 3 mo
___Counseling  
      provided4
___Not provided 
(medical reasons*) 
___Counseling  
      provided4
___Not provided 
      (medical reasons*)
___Counseling  
      provided4
___Not provided 
      (medical reasons*) 
___Counseling  
      provided4
___Not provided 
      (medical reasons*) 
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Ed
uc
at
io
n
Patient self-care 
education 
(Quality improvement only) 
___Patient education  
    provided5
___Patient education  
      provided5
___Patient education  
      provided5
___Patient education  
      provided5
*Specify medical reasons (eg, not indicated, contraindicated), patient reasons (eg, patient declined, social, religious), system reasons (eg, 
resources to perform services not available, insurance coverage/payer-related limitations) for not performing any of the above:
1NYHA functional classification categories are as follows: Class I: patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical
tivity does not cause undue fatigue, palpitation, dyspnea, or anginal pain; Class II: patients with cardiac disease resulting in slight limitation of physical activity.
tients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain; Class III: patients with marked limitation of physical
tivity. Patients are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain; Class IV: patients with cardiac disease
sulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present even at rest. If any physical
tivity is undertaken, discomfort is increased. Valid, reliable, disease-specific patient-reported questionnaires include the Kansas City Cardiomyopathy Questionnaire
CCQ); Minnesota Living with Heart Failure Questionnaire (MLHFQ); and Chronic Heart Failure Questionnaire (CHFQ).
2Patient symptoms have demonstrated clinically important deterioration since last assessment.
3A documented plan of care may include 1 of the following: reevaluation of medical therapy, including uptitration of doses, consideration of electrical device
erapy, recommended lifestyle modifications (e.g., salt restriction, exercise training), initiation of palliative care, referral for more advanced therapies (e.g., transplant,
ntricular assist device), or referral to disease management programs.
4Counseling should be specific to each individual patient and include documentation of a discussion regarding the risk of sudden and nonsudden death AND the
ficacy, safety, and risks of an ICD. This will allow patients to be informed of the risks and benefits of ICD implantation and to be better able to make decisions based
the valuation of sudden cardiac death vs other risks.
5Must include 3 of the following elements: definition of heart failure (linking disease, symptoms, and treatment) and cause of patient’s heart failure; recognition
escalating symptoms and concrete plan for response to particular symptoms; indications and use of each medication; modify risk for heart failure progression;
ecific diet recommendations; individualized low-sodium diet; recommendation for alcohol intake; specific activity/exercise recommendations; importance of
atment adherence and behavioral strategies to promote treatment adherence.
